Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Owens Corning and its officers/directors following a significant financial loss reported in Q3 2025 [1][2]. Financial Performance - Owens Corning reported a net loss of $495 million, or $5.93 per diluted share, for Q3 2025, a stark contrast to a net income of $287 million, or $3.26 per share, in the same period of 2024 [2]. - The loss was primarily attributed to a $780 million non-cash impairment charge related to the Company's doors business [2]. - The Company anticipates a decline in revenue for Q4 2025, projecting between $2.1 billion and $2.2 billion due to soft residential markets and reduced demand for storm-related roofing [2]. Market Reaction - Following the announcement of the financial results, Owens Corning's stock price fell by $11.69 per share, or 9.53%, closing at $111.03 per share on November 5, 2025 [2].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Savers Value Village, Inc. and its officers or directors [1]. Group 1: Company Overview - Savers Value Village, Inc. conducted its initial public offering (IPO) on June 29, 2023, offering 25,635,415 shares at a price of $18.00 per share [2]. - The company reported a non-GAAP profit of $0.14 per share for the third quarter of 2025, but a GAAP loss of $0.09 per share [2]. Group 2: Market Reaction - Following the financial results announcement, Savers' stock price dropped by $4.02, or 30.39%, closing at $9.21 per share on October 31, 2025 [2].

Core Insights - Varonis Systems, Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results [1][2] Financial Performance - On October 28, 2025, Varonis reported third-quarter financial results that missed consensus estimates, including a significant 63.9% year-over-year decline in term license subscription revenues [2] - The company reduced its full-year Annual Recurring Revenue (ARR) guidance due to underperformance in its on-premises subscription business [2] - CEO Yakov Faitelson indicated that the on-premises subscription business is negatively impacting overall company ARR growth, citing lower renewal rates and sales process issues as contributing factors [2] Stock Market Reaction - Following the announcement of the financial results, Varonis's stock price dropped by $30.66 per share, or 48.67%, closing at $32.34 per share on October 29, 2025 [2]

Core Insights - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving VirTra, Inc. and its officers or directors [1] - VirTra reported third-quarter 2025 financial results, with GAAP earnings per share of -$0.03, missing consensus estimates by $0.07, and revenue of $5.3 million, missing consensus by $1.69 million [2] - Following the earnings report, VirTra's stock price decreased by $0.43, or 7.93%, closing at $4.99 per share on November 11, 2025 [2] Financial Performance - VirTra's GAAP earnings per share for Q3 2025 were -$0.03, which was below the consensus estimate by $0.07 [2] - The company's revenue for the same period was reported at $5.3 million, missing the consensus estimate by $1.69 million [2] - The CEO indicated that a slower federal funding cycle and the timing of federal awards impacted near-term revenue recognition [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Western Alliance Bancorporation and its officers or directors [1]. Group 1: Legal Actions and Stock Impact - On October 16, 2025, Western Alliance filed a lawsuit against Cantor Group V LLC, alleging fraud related to collateral loans [2]. - Following the lawsuit announcement, Western Alliance's stock price dropped by $8.52 per share, representing a decline of 10.81%, closing at $70.32 per share [2]. Group 2: Pomerantz LLP Overview - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in the field [3]. - The firm has successfully recovered numerous multimillion-dollar damages awards for victims of securities fraud and corporate misconduct [3].

Core Viewpoint - Beyond Meat, Inc. is under investigation for potential violations of federal securities laws, particularly concerning the inflation of the value of certain long-lived assets [2][5]. Group 1: Company Operations and Financials - Beyond Meat underwent a global operations review in late 2023, leading to the depreciation of certain long-lived assets, which were recorded at the lower of their carrying value or fair value less costs to sell, with no impairments reported [4]. - On October 24, 2025, Beyond Meat announced an expected non-cash impairment charge for the three months ended September 27, 2025, related to certain long-lived assets, which was anticipated to be material [6]. - The company delayed its earnings announcement for Q3 2025 on November 3, 2025, due to the need for additional time to complete the impairment review, resulting in a significant decline in stock price during that trading day [7]. Group 2: Stock Performance - Following the announcement of the expected impairment charge, Beyond Meat's stock price dropped approximately 23%, from $2.84 per share on October 23, 2025, to $2.185 per share on October 24, 2025 [6].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics for potential violations of federal securities laws, with a significant deadline for investors to act by December 15, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [3]. - Investors are encouraged to contact BFA Law for more information and to potentially lead the case [2][8]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [4]. - The company conducted Phase 3 VELA trials for sonelokimab (SLK), aimed at treating moderate to severe hidradenitis suppurativa [4]. Group 3: Allegations and Impact - The complaint alleges that MoonLake misrepresented its clinical data and the benefits of SLK's Nanobody structure compared to traditional monoclonal antibody treatments [5][6]. - Following the announcement of disappointing results from the VELA trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 to $6.24 per share [7].

Core Viewpoint - RCI Hospitality Holdings, Inc. is facing a securities fraud class action lawsuit due to allegations of tax fraud and bribery involving its executives, which has resulted in a significant drop in its stock price [2][3][4]. Summary by Sections Company Overview - RCI Hospitality Holdings, Inc. (NASDAQ: RICK) is under scrutiny following the indictment of its top executives for involvement in a multimillion-dollar criminal tax fraud and bribery scheme [2]. Legal Proceedings - A class action lawsuit has been filed on behalf of investors who acquired RCI securities between December 15, 2021, and September 16, 2025, with a deadline of November 20, 2025, to participate as a lead plaintiff [1][5]. Allegations - The lawsuit alleges that RCI's executives made materially false and misleading statements and failed to disclose significant adverse facts about the company's operations, including: 1. Engagement in tax fraud 2. Bribery to conceal tax fraud 3. Understated legal risks facing the company 4. Misleading positive statements regarding the company's business and prospects [4]. Market Impact - Following the announcement of the indictments on September 16, 2025, RCI's stock price fell by $5.53, or 15.9%, closing at $28.79, which has adversely affected investors [3].

Core Viewpoint - Iron Mountain Inc. is under investigation for potential securities law violations following a report from Gotham City Research that alleges the company has understated its leverage and inflated adjusted EBITDA, while also facing customer lawsuits regarding fee increases and aggressive practices [2][4]. Group 1: Company Allegations - Gotham City Research claims that Iron Mountain has understated its leverage and inflated adjusted EBITDA through recurring add-backs [2]. - The report also highlights customer lawsuits accusing Iron Mountain of imposing sharply higher fees and engaging in "ransom-like" practices related to record retrieval and destruction [2]. Group 2: Investigation and Legal Actions - Block & Leviton is investigating Iron Mountain for potential securities law violations and may file an action to recover losses for affected investors [4]. - Investors who have lost money on their Iron Mountain investments are encouraged to contact Block & Leviton for more information on recovery options [3][5]. Group 3: Whistleblower Information - Individuals with non-public information about Iron Mountain are encouraged to assist in the investigation or report to the SEC under the whistleblower program, with potential rewards of up to 30% of any successful recovery [6]. Group 4: Firm Background - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Core Viewpoint - A class action lawsuit has been filed against Perrigo Company plc for alleged securities fraud, impacting shareholders who purchased securities between February 27, 2023, and November 4, 2025 [1][11]. Group 1: Company Actions and Financial Performance - In November 2022, Perrigo acquired Nestlé's Gateway infant formula plant and the rights to the Good Start infant formula brand for $170 million [3]. - On February 27, 2024, Perrigo reported fiscal year 2023 earnings, revealing acquisition-related charges of $35 million to $45 million for remediation in the infant formula business, leading to a 50% decline in earnings per share compared to the previous year [4]. - Following this announcement, Perrigo's share price fell by $4.87, or 15.14%, closing at $27.30 on February 27, 2024 [5]. - On May 7, 2024, Perrigo reported a 34.5% decrease in net sales to $91 million and a decline in gross margin by 90 basis points, while maintaining that cash costs for remediation would remain flat at $35 to $45 million [6]. - The share price dropped by $3.28, or 9.8%, to close at $30.15 on May 7, 2024 [7]. - On August 6, 2025, Perrigo announced scrapping approximately $11 million of inventory due to production issues, with the CFO stating that recovery in the infant formula business was progressing [8]. - The share price fell by $3.01, or 11.31%, to close at $23.61 on August 6, 2025 [8]. - On November 5, 2025, Perrigo initiated a strategic review of its infant formula business and cut its fiscal year 2025 outlook, revising net sales growth guidance to -2.5% to -3% from a previous expectation of 0% to 3% [9]. - The stock price plummeted by $5.09, or 25.2%, to close at $15.10 on November 5, 2025 [10]. Group 2: Allegations in the Lawsuit - The lawsuit alleges that Perrigo made materially false and misleading statements and failed to disclose adverse facts about its business and operations, including significant underinvestment in the acquired infant formula business and the need for substantial capital expenditures for remediation [11]. - It is claimed that manufacturing deficiencies in the infant formula facility led to overstated financial results, including earnings and cash flow, and that positive statements made by the company lacked a reasonable basis [11].